- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 02:46 | Electra amasses $350M in biotech's latest big IPO | ||
| Do | Novo partners with Orbis, deepening investment in oral peptide drugs | ||
| Do | North Immunology joins biotech reverse merger boom with Aethlon deal | ||
| Do | Roche, Dualitas team up to find bispecific drugs for immune diseases | ||
| Mi | Novartis to pay $125M for blood-brain barrier crossing platform | ||
| Mi | Novo looks to Anthropic's AI models to 'supercharge' drug development | ||
| Mi | Sling banks $123M for an experimental thyroid eye disease pill | ||
| Di | FDA clears first generic radioligand drug; Sionna turns to layoffs | ||
| Di | WCLC '26: A new 'ADC era,' China questions and AstraZeneca's spotlight | ||
| Di | FDA launches pilot program to speed up early US drug research | ||
| Mo | Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results | ||
| Mo | AstraZeneca's newly approved pill fails frontline breast cancer study | ||
| Mo | Cellectis quits CAR-T and pivots to 'in vivo' gene editing | ||
| Mo | Scholar Rock SMA drug approved by FDA | ||
| 11.09. | This week in charts: RA's insatiable appetite, Novartis' big slide and a reverse merger spree | ||
| 11.09. | Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use | ||
| 11.09. | mRNA cancer vaccines' biggest barriers to market | ||
| 10.09. | FDA places partial hold on Biohaven's epilepsy drug | ||
| 10.09. | Andy Plump, architect of Takeda's R&D overhaul, to retire next year | ||
| 10.09. | A booming business on Wall Street would love more biotechs to quietly die | ||
| 09.09. | Tyra disappoints investors with bladder cancer data | ||
| 09.09. | Kura spins diabetes work into a Lilly-backed biotech startup | ||
| 09.09. | FDA gains 'continuity' as Mikhail, Davis named permanent CBER, CDER leaders | ||
| 09.09. | A new immuno-oncology play raises $225M for a next-generation drug | ||
| 09.09. | Six AI agents, one deskside system: A new model for clinical decision support |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.